Search

1 to 10 of 170
Sort by

Library Entry
Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies

Predicting metastasis in melanoma patients is important for disease management and could help to identify those who might benefit from adjuvant treatment. The aim of this study was to investigate whether the tumor microenvironment-derived protein S100A8/A9 qualifies as prognostic marker for...


Library Entry
Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient

Immune checkpoint inhibitors (ICPis) have revolutionised the treatment of melanoma by significantly increasing survival rates and disease control. However, ICPis can have specific immune-related adverse events, including rare but severe neurological toxicity. The authors report the first case of...


Library Entry
Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC

Currently, there are no imaging predictors of immunotherapy outcome in hepatocellular carcinoma (HCC). The study aim was to determine if stiffness changes measured by magnetic resonance elastography (MRE) can be a predictor of immunotherapy response in patients with advanced HCC. The authors...


Library Entry
Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature

Neurologic complications such as myelitis are very rare but extremely deleterious adverse effects of both immunotherapy and radiotherapy. Many recent studies have focused on the possible synergy of these two treatment modalities due to their potential to enhance each other’s immunomodulatory...



Library Entry
Immunotherapy for the Treatment of Head & Neck Cancers - A Patient Resource Guide

Learning you have head and neck cancer can fell overwhelming. Give yourself time to digest the news, and then focus on learning as much as you can about your exact diagnosis. Knowing ket information will better prepare you to make well-informed decisions with your doctor. This guide, published...

2019 Immunotherapy H&N.pdf


Library Entry
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy without good treatment options. There are limited data about the use of immunotherapy in ACC. The authors investigated the efficacy and safety of pembrolizumab in patients with metastatic ACC. They concluded that single-agent pembrolizumab has...


Library Entry
Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab

The authors present a case of sequential immune-related adverse events (irAEs) in a patient with metastatic melanoma treated with single-agent anti-programmed cell death-1 (PD-1) therapy, pembrolizumab. Although numerous cases of irAEs have been reported, sequential multi-organ involvement,...


Library Entry
Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature

Autoimmune polyendocrine syndrome type II (APS-2) is a rare constellation of autoimmune hypoadrenalism, thyroid dysfunction and/or type 1 diabetes (T1DM), usually occurring in the 3rd or 4th decades and associated with a human leukocyte antigen (HLA) DR3 or DR4 serotype. The authors detail the...